Guardant Health, Inc. - Common Stock (NQ:GH)

177.80 +3.05 (+1.75%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Guardant Health, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

22 23 Next >

Cathie Wood's Ark Invest Offloads Meta, Loads Up On Teradyne, Caris Life Sciences ↗

July 19, 2025

Ark Invest made significant trades in TER, META, CAI, and GH. Wood's emphasis on AI's impact on jobs aligns with their purchases and sales.

Via Benzinga

Topics Artificial Intelligence

First Patient Enrolled in National Cancer Institute’s Vanguard Study Evaluating Guardant Health’s Shield Multi-Cancer Detection Test

July 15, 2025

From Guardant Health, Inc.

Via Business Wire

Guardant Health to Report Second Quarter 2025 Financial Results on July 30, 2025

July 14, 2025

From Guardant Health, Inc.

Via Business Wire

Guardant Health, Gilead Sciences, Inspire Medical Systems, Enovis, and AMN Healthcare Services Stocks Trade Down, What You Need To Know

July 11, 2025

A number of stocks fell in the afternoon session after the U.S. administration announced a sharp escalation in trade tensions by threatening new tariffs on Canada.

Via StockStory

Topics ETFs Stocks World Trade

Could Personalized Medicine Be Your Portfolio's Next Big Winner? Find Out ↗

June 25, 2025

BofA analysts review the promise and limits of AI in precision medicine, highlighting key players like Tempus, Guardant, and Exact Sciences.

Via Benzinga

Topics Artificial Intelligence

3 Cash-Burning Stocks Facing Headwinds

June 16, 2025

While some companies burn cash to fuel expansion, others struggle to turn spending into sustainable growth. A high cash burn rate without a strong balance sheet can leave investors exposed to...

Via StockStory

3 of Wall Street’s Favorite Stocks Facing Headwinds

June 13, 2025

Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings,...

Via StockStory

2 Mooning Stocks Worth Your Attention and 1 to Be Wary Of

June 11, 2025

The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial...

Via StockStory

Guardant Health Wins Fast Company’s 2025 World Changing Ideas Award for Shield Blood Test for Colorectal Cancer Screening

June 10, 2025

From Guardant Health, Inc.

Via Business Wire

New Study Published in ESMO Open Highlights Guardant Reveal's Performance in Detecting Minimal Residual Disease in Patients with Early-Stage Breast Cancer

June 09, 2025

From Guardant Health, Inc.

Via Business Wire

Cathie Wood's ARK Invest Buys More Amazon Stock: Retail Still On The Sidelines ↗

June 03, 2025

The widely watched investor also bought AMD and Guardant Health stocks, while cutting its stakes in CoreWeave and Palantir.

Via Stocktwits

Topics ETFs World Trade

Why Guardant Health Stock Surged Nearly 9% Higher Today ↗

June 03, 2025

Via The Motley Fool

Why Is Cancer Diagnostic Guardant Health Stock Trading Higher On Tuesday? ↗

June 03, 2025

Guardant Health's Shield test receives FDA breakthrough status and NCCN guideline inclusion, with high accuracy shown in new ASCO and ECLIPSE study data.

Via Benzinga

Signet Posts Upbeat Earnings, Joins Ferguson Enterprises, Dollar General And Other Big Stocks Moving Higher On Tuesday ↗

June 03, 2025

Via Benzinga

FDA Grants Breakthrough Device Designation to Guardant Health’s Shield Multi-Cancer Detection (MCD) Test

June 03, 2025

From Guardant Health, Inc.

Via Business Wire

National Comprehensive Cancer Network (NCCN) Updates Colorectal Cancer Screening Guidelines to Include Shield Blood-Based Screening

June 02, 2025

From Guardant Health, Inc.

Via Business Wire

SERENA-6 Phase III Trial Demonstrates Clinical Value of Guardant360 CDx Test to Detect Emergence of Endocrine Resistance and Inform a Switch in Therapy Before Radiological Disease Progression in Advanced Breast Cancer

June 02, 2025

From Guardant Health, Inc.

Via Business Wire

In Largest Molecular Residual Disease (MRD) Study in Colon Cancer, Guardant Reveal Testing Prior to Chemotherapy Provides Robust Stratification for Risk of Disease Recurrence and Survival to Enable Timely Treatment Decisions

May 31, 2025

From Guardant Health, Inc.

Via Business Wire

2 Growth Stocks with Impressive Fundamentals and 1 to Question

May 30, 2025

Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market’s...

Via StockStory

Firing on All Cylinders: Guardant Health (NASDAQ:GH) Q1 Earnings Lead the Way

May 27, 2025

As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the testing & diagnostics services industry, including Guardant Health (NASDAQ:GH) and...

Via StockStory

Guardant Health Introduces Nearly a Dozen Groundbreaking Smart Liquid Biopsy Applications for Guardant360 Liquid Test

May 27, 2025

From Guardant Health, Inc.

Via Business Wire

Guardant Health and Collaborators to Present Over 19 Studies Demonstrating Role of Liquid Biopsy in Advancing Precision Oncology at 2025 ASCO Annual Meeting

May 22, 2025

From Guardant Health, Inc.

Via Business Wire

Guardant Health, Evolent Health, Charles River Laboratories, Avantor, and Lumen Stocks Trade Down, What You Need To Know

May 21, 2025

A number of stocks fell in the afternoon session after the major indices pulled back (Nasdaq -1.3%, S&P 500 - 1.4%) as Treasury yields rose, reflecting market anxiety over a draft federal budget that...

Via StockStory

Topics Bonds Stocks

Guardant Health Introduces Comprehensive Immunohistochemistry Testing for Solid Tumors

May 21, 2025

From Guardant Health, Inc.

Via Business Wire

Guardant Health Introduces Hereditary Cancer Testing to Identify Inherited Predispositions to Certain Types of Cancer

May 20, 2025

From Guardant Health, Inc.

Via Business Wire

Guardant Health: A Promising Player in the Liquid Biopsy Market ↗

May 16, 2025

Via The Motley Fool

GH Q1 Earnings Call: Guardant Health Lifts Full-Year Guidance Following Oncology and Screening Momentum

May 14, 2025

Diagnostics company Guardant Health (NASDAQ:GH) announced better-than-expected revenue in Q1 CY2025, with sales up 20.8% year on year to $203.5 million. The company’s full-year revenue guidance of $885...

Via StockStory

2 Volatile Stocks Worth Investigating and 1 to Steer Clear Of

May 12, 2025

Market swings can be tough to stomach, and volatile stocks often experience exaggerated moves in both directions. While many thrive during risk-on environments, many also struggle to maintain investor...

Via StockStory

Topics Stocks

10 Health Care Stocks With Whale Alerts In Today's Session ↗

May 09, 2025

Via Benzinga

Guardant Health to Participate in Upcoming Investor Conferences

May 08, 2025

From Guardant Health, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

22 23 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.